Physician profile
Thomas D Holley
NPI 1205026846
$2,027.33
in general payments reported to CMS, 2019-2025
30 companies · $339 in 2025
The $339 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $251 · 2021: $104 · 2022: $228 · 2023: $187 · 2024: $576 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $409.20 | 2019-2024 | |
| Procept Biorobotics Corporation | $218.75 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Astellas Pharma US INC | $203.01 | 2019-2025 | Xtandi |
| Ethicon US, LLC | $144.54 | 2023-2025 | Vistaseal, Surgiflo Hemostatic Matrix, Dermabond |
| Urogen Pharma, INC. | $107.96 | 2022-2025 | |
| Allergan, INC. | $105.75 | 2020 | |
| Pfizer INC. | $104.58 | 2020-2025 | |
| Antares Pharma, INC. | $98.00 | 2021-2025 | Xyosted |
| Endo Pharmaceuticals INC. | $97.20 | 2021-2023 | Xiaflex |
| Abbvie INC. | $90.28 | 2022-2025 | |
| Medtronic, INC. | $69.00 | 2021-2023 | Interstim |
| Ferring Pharmaceuticals INC. | $34.34 | 2025 | Adstiladrin |
| Verity Pharmaceuticals INC. | $33.80 | 2025 | Tlando |
| Immunitybio, INC. | $27.58 | 2025 | |
| Baxter Healthcare | $25.65 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Civco Medical Instruments | $25.02 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $23.83 | 2022 | |
| Laborie Medical Technologies Corp. | $21.71 | 2025 | |
| Rochester Medical Corporation | $21.64 | 2020 | |
| Urovant Sciences INC | $20.69 | 2022 | |
| Coloplast Corp | $18.80 | 2022 | |
| Sumitomo Pharma America, INC. | $18.61 | 2025 | Gemtesa |
| Olympus America INC. | $17.86 | 2024 | Bovie |
| Merck Sharp & Dohme LLC | $16.30 | 2021 | |
| Janssen Biotech, INC. | $16.07 | 2025 | Erleada |
| Genzyme Corporation | $15.56 | 2020 | |
| Axonics, INC. | $13.76 | 2023 | Axonics |
| Amgen INC. | $11.95 | 2019 | |
| Ambu INC. | $8.25 | 2020 | |
| Travere Therapeutics, INC. | $7.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Holley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.